Hemodiafiltration: Clinical Evidence of Higher Benefit Reference: Blankestijn PJ, LedeboI, Canaud B. Hemodiafiltration: Clinical evidence and remaining.

Slides:



Advertisements
Similar presentations
Agency for Healthcare Research and Quality (AHRQ)
Advertisements

In the name of GOD In the name of GOD.
RENAL REPLACEMENT THERAPY
Acute Renal Replacement Therapy for the Infant Dr.Fahad Gadi, MD Pediatrics Demonstrator King Abdulaziz University Rabigh Medical School.
Pediatric CRRT: Terminology and Physiology
Hemodiafiltration and Hemofiltration
Hemodialysis vs. Hemodiafiltration
Hemodialysis Adequacy
M ETABOLIC S YNDROME IN P ERIONIAL D IALYSIS Dr. Sreelatha Calicut.
MANAGEMENT OF CONTINUOUS HEMODIALYSIS
Statins in Renal Failure Andrea Fox Sunnybrook Health Science Center May 2010.
Measurement and preservation of residual renal function (RRF) in haemodialysis patients Elizabeth Lindley and David Keane Leeds Teaching Hospitals NHS.
EDWARD WELSH MARCH Dialysis Adequacy (?).
Topic 12 – Further Topics in ANOVA
Neel Bhalala (2009) Sofia Medical University. Background  Erythropoiesis-stimulating agents are man-made versions of a natural protein known as erythropoietin.
Departments of Medicine and Biostatistics
Elimination of Phosphate in HD and PD Reference: Kuhlmann MK. Phosphate elimination in modalities of hemodialysis and peritoneal dialysis. Blood Purif.
Reference Avram MM, et al. Hemoglobin predicts long-term survival in dialysis patients: a 15-year single-center longitudinal study and a correlation trend.
Estimation and Reporting of Heterogeneity of Treatment Effects in Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare.
Incorporating considerations about equity in policy briefs What factors are likely to be associated with disadvantage? Are there plausible reasons for.
Journal Club Alcohol and Health: Current Evidence May–June 2005.
Journal Club Alcohol and Health: Current Evidence January–February 2007.
By Dr. Ahmed Mostafa Assist. Prof. of anesthesia & I.C.U. Evidence-based medicine.
Sample Size Determination Ziad Taib March 7, 2014.
HEMODIALYSIS DIALYZER
Approach to Advanced Kidney Disease Management in the Elderly Source: Schell JO, Germain MJ, Finkelstein FO, et al. An integrative approach to advanced.
Hemoglobin A 1c in Hemodialysis Patients Source: Ix JH. Hemoglobin A1c in hemodialysis patients: Should one size fit all? Clin J Am Soc Nephrol. 2010;5:1539–1541.
How to manage anaemia in HD patients
Urinary System. Secreted Substances Secreted Substances Hydroxybenzoates Hydroxybenzoates Hippurates Hippurates Neurotransmitters (dopamine) Neurotransmitters.
Landmark developments in dialysis
Individualizing Targets and Tactics for High- Risk Patients With Type 2 Diabetes Practical lessons from ACCORD and other cardiovascular trials Featured.
Dose Adjustment in Renal and Hepatic Disease
How Technological Developments make better Treatment a Reality
Peritoneal Dialysis for Elderly Patients: A Review Source: Tesar V. Peritoneal dialysis in the elderly—is its underutilization justified? Nephrol Dial.
CLAIMS STRUCTURE FOR SLE Jeffrey Siegel, M.D. Arthritis Advisory Committee September 29, 2003.
Copyright © Cengage Learning. All rights reserved. 10 Inferences Involving Two Populations.
Renal Replacement Therapy in Intoxications Maria Ferris, MD, MPH, PhD University of North Carolina Kidney Center Chapel Hill, North Carolina USA 7/17/2015.
APPLICATION OF INDIVIDUALIZED BAYESIAN UREA KINETIC MODELING TO PEDIATRIC HEMODIALYSIS Olivera Marsenic, Athena Zuppa, Jeffrey S. Barrett, Marc Pfister.
Mixed models. Concepts We are often interested in attributing the variability that is evident in data to the various categories, or classifications, of.
Common Prescription Errors in Pediatric CRRT: a “Top 10 List” Jordan M. Symons, MD University of Washington School of Medicine Seattle Children’s Hospital.
Common Terminology Used and Physiology in CRRT Jordan M. Symons, MD University of Washington School of Medicine Seattle Children’s Hospital Seattle, WA.
Sifting through the evidence Sarah Fradsham. Types of Evidence Primary Literature Observational studies Case Report Case Series Case Control Study Cohort.
Online-HDF the superior quality of treatment Thomas Ryzlewicz.
N.L Mufute , LWRM, MSU / PRELIMINARY DESIGN STEPS AND SPRINKLER SELECTION –EXAMPLE ON PERIODIC-MOVE SYSTEMS N.L.
9-1 ESTIMATION Session Factors Affecting Confidence Interval Estimates The factors that determine the width of a confidence interval are: 1.The.
PCRRT Tûr'mə-nŏl'ə-jē Helen Currier BSN, RN, CNN Assistant Director, Renal/Pheresis Texas Children’s Hospital Houston, Texas.
Continuous Renal Replacement Therapy Developed by: Critical Care and Hemodialysis Educators, February 2009 King Faisal Specialist Hospital and Research.
High Coronary Calcification Scores Predict Mortality in Pre-Dialysis CKD Patients Reference: Haas MH. The risk of death in patients with a high coronary.
Medical Technology and Practice Patterns Institute 4733 Bethesda Ave., Suite #510 Bethesda, MD Phone: Fax: Comparison of.
The balANZ Trial. Source Johnson DW, Clarke M, Wilson V, et al. Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral.
Risk Involved with Dual RAAS Blockade in Kidney Disease Source: Bakris GL. Dual RAAS blockade is desirable in kidney disease: Con. Kidney Int. 2010;78:546–549.
The DVD Trial. Source Reinecke H, Fobker M, Wellmann J, et al. A randomized controlled trial comparing hydration therapy to additional hemodialysis or.
Rajeev Annigeri. Apollo Hospitals, Chennai.
به نام خدا Dialysis Adequacy KT/V and beyond Mohammad Taghi Najafi Assistant Professor of nephrology Tehran University of Medical Science Aug 2016.
Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children: Cardiovascular.
World Kidney Day 2016: Kidney Disease & Children
The ALERT Trial.
When Using DOPPS Slides
HAEMODIALYSIS Shofa chasani.
Pancreas Transplantation Committee
The HEMO Study Hemodialysis (HEMO) Study Reference
Quantification and Dosing of Renal Replacement Therapy in Acute Kidney Injury: A Reappraisal Blood Purif 2017;44: DOI: / Fig.
The ADEMEX Trial Adequacy of PD in Mexico Reference
Spotlight on general principles of hemodialysis
Fan et al. Am J Nephrol 2017;45:   (DOI: / )
Volume 54, Issue 3, Pages (September 1998)
Basics of CRRT: Terminology
Continuous Renal Replacement Therapy
Joachim Böhler, M.D., Johannes Donauer, Frieder Keller 
Dialysis limitations. Dialysis limitations. (A) Recent data from observational studies and randomized, clinical trials indicate significant limitations.
Presentation transcript:

Hemodiafiltration: Clinical Evidence of Higher Benefit Reference: Blankestijn PJ, LedeboI, Canaud B. Hemodiafiltration: Clinical evidence and remaining questions. Kidney International. 2010;77:581–587.

Worldwide, hemodialysis (HD) using high-flux membranes are currently well accepted (see Fig. 1). The rationale of its use is that it offers enhanced clearance of various uremic toxins by combining diffusion with some degree of convective transport within the dialyzer, which could be of relevance in determining clinical outcome.

However, two large randomized trials failed to show any survival benefits for the general HD population, when high flux dialysis was compared with dialysis with standard low flux membranes. Notably, the subgroups which did not benefit with the procedures were identified in both trials. This fact can be interpreted as showing that the intervention was useful only in certain high-risk patients but was not powerful enough to affect all patients. Moreover, harmful effects associated with high-flux membranes were not reported in any of the studies. As a result, the clinical data on hemodiafiltration (HDF), a technique that offers a greater advantage in clearance of various types of uremic toxins than HD with low- and high-flux membranes, was reviewed. The following review details about applying online HDF; as this technique has the potential to give the most pronounced enhanced clearance as compared to standard HD and other modes of HDF, and consequently conferring the greatest likelihood of benefit to the patient.

Technical Issues Associated with HD The ultrafiltration of fluid is required by the convective transport, to an extent that exceeds the desired weight loss. Moreover, fluid balance is maintained by infusion of a replacement fluid, also known as substitution fluid; which can be provided in industrially prepared, autoclaved, plastic bags. Logistically, this is troublesome and expensive, and hence is not widely accepted. Conversely, online HDF gives the option of quality-controlled, stepwise ultrafiltration. The substitution fluid is mixed with the blood and should therefore be sterile and non-pyrogenic with a composition similar to plasma water. Moreover, this high quality has to be continuously present.

Removal of Solute: Results with Online HDF Uremic toxins can be categorized into three groups: – Free water-soluble low-molecular-weight solutes, such as urea and creatinine – Middle-sized solutes, such as β 2 -microglobulin (β 2 m) – Protein-bound solutes, such as p-cresol An increase in small solute clearance is usually seen during the switch-over from either low- or high-flux HD to online HDF. This increase is modest as small solute clearance is mainly diffusive and therefore already very effective during HD. However, the removal of β 2 m is clearly increased during online HDF, and clearance of solutes in the middle molecule range might be of clinical relevance.

Removal of Solute: Results with Online HDF In the Hemodialysis (HEMO) Study, predialysis β 2 m levels predicted mortality, and several observational and randomized studies have shown that predialysis levels decrease when patients are switched to online HDF. A crossover study in which patients went from high-flux HD to online HDF and back, reported that online HDF markedly reduced production of TNF-α and IL-6 in addition to proinflammatory CD14+CD16+ cells. Improvement of variables related to endothelial dysfunction, oxidative stress, and antioxidant capacity was also attributed to the use of online HDF, besides this modality has shown to reduce advanced glycation end- products more effectively than high-flux dialysis. Thus, several lines of evidence testify that use of online HDF is associated with enhanced clearance small molecules, and several types of other molecules that might be of relevance in the pathogenesis of uremic and cardiovascular complications.

Clinical Variables Associated with Online HDF An improvement of clinically meaningful variables is associated with online HDF since it removes substances in a broader range of molecular size compared to conventional low-flux HD. Several studies suggested that online HDF was associated with an improvement of hemodynamic stability and blood pressure control; however certain other studies failed to confirm this. The difference in hemodynamic stability disappeared when online HDF was compared with temperature-controlled HD. Thus, this effect seemed to be mainly caused by cooling of the blood by enhanced thermal energy losses within the extracorporeal system in online HDF rather than from increasing solute removal. Studies also reported an improvement of nutritional parameters in patients when they were switched to online HDF.

Use of HDF: Effect on Survival Benefit Several retrospective analyses suggested that there could be a survival benefit in patients treated with HDF. Even after correction for various confounding factors, the use of high-efficiency HDF in the Dialysis Outcomes and Practice Patterns Study (DOPPS) cohort (replacement volume of more than 15 litres per session, which means online HDF in most cases for obvious logistical reasons) was associated with a 35% lower mortality risk. On the contrary, low efficiency HDF (replacement volume less than 15 litres per session) was not associated with any significant reduction of risk. A 37% mortality risk reduction was reported by another large observational study from Eastern Europe studying the effect of online HDF.

Use of HDF: Effect on Survival Benefit A single-center retrospective analysis from the United States reported that the standardized mortality ratio for patients treated with HDF (double high-flux HDF) was 0.41, indicating an almost 60% lower risk of mortality. Furthermore, a large Italian observational study suggested a survival benefit in patients on online HDF. Quite recently, a UK dialysis unit with long experience of HDF reported the outcome from some 150,000 sessions of online HDF compared with twice as many sessions of high-flux HD. They identified that the patients predominantly treated with HDF had a 34% lower mortality risk. Therefore, it can be hypothesized based on the evidence outlined above, that online HDF offers a superior treatment modality as compared to standard HD therapy.

Summary Penne et al. outlined the summary of factors that determined ultrafiltration. In addition to hematocrit, which is an important factor; modifiable treatment-related factors include treatment time and extracorporeal blood flow. Within the hematocrit range presently advised by Guidelines, the relation between ultrafiltration rate (i.e., convection) and extracorporeal blood flow rate can be 25– 35%. Table 1 lists the summary of the basic requirements which may guide the clinician to perform online HDF in everyday clinical practice. In conclusion, combining diffusive and convective strategies offers an interesting option. Currently, widely accepted is the standard use of high-flux membranes in HD, which can be considered as a ‘poor man’s HDF’. By applying online HDF, the combination of diffusive and convective transport can most efficiently be obtained, since it can provide larger convection volumes without major practical and economic constraints. The DOPPS findings provide the only data relating dose, which is convection volume per session, with clinical outcome. Currently available water treatment equipment and dialysis machines make it possible to perform online HDF on considerable scale in everyday clinical practice, besides suitable equipments are available with the main dialysis industries.

Comprehensive Basket in Anemia Management